The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu vaccines in the U.S. More than 18,000 adults, most of them in the U.S., were ...
FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 ...
More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...
Newser on MSN
Pfizer's New Flu Shot Could Be a 'Game Changer'
A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...
Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...
SAN FRANCISCO -- As more people are getting vaccinated, medical experts in the United Kingdom and the U.S are holding trials to find out if giving two doses of a different COVID vaccine improves your ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback